Chemotherapy and Radiotherapy for Osteolymphoma

NACompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

September 30, 2000

Primary Completion Date

February 28, 2007

Study Completion Date

February 29, 2008

Conditions
Osteolymphoma
Interventions
DRUG

Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone.

Given intravenously on days 1,11,43: Cyclophosphamide 750mg/m2, doxorubicin 50mg/m2, vincristine 1.4mg/m2. Given orally on days 1-5,22-27: Pednisolone 50mg/m2

RADIATION

Radiotherapy

Total 45 Gy in 25 fractions

Trial Locations (20)

1001

Auckland Hospital, Auckland

1871

Liverpool Hospital, Liverpool

2050

Royal Prince Alfred Hospital, Camperdown

2145

Westmead Hospital, Wentworthville

2310

Calvary Mater Newcastle, Newcastle

3002

Peter MacCallum Cancer Centre, East Melbourne

3200

Waikato Hospital, Hamilton

3220

Andrew Love Cancer Care Centre, Geelong Hospital, Geelong

4006

The Wesley Radiation Oncology Pty Ltd, Auchenflower

4029

Royal Brisbane Hospital, Herston

4101

Mater QRI, South Brisbane

4102

Princess Alexandra Hospital, Woolloongabba

4224

East Coast Cancer Centre, John Flynn Hospital, Tugun

4810

North Queensland Oncology Service, Townsville

5000

Royal Adelaide Hospital, Adelaide

6009

Sir Charles Gairdner Hospital, Nedlands

7000

Royal Hobart Hospital, Hobart

7250

Launceston General Hospital, Launceston

Unknown

Wollongong Hospital, Wollongong

Palmerston North Hospital, Palmerston North

All Listed Sponsors
collaborator

Australasian Leukaemia and Lymphoma Group

OTHER

collaborator

Australasian Radiation Oncology Lymphoma Group

OTHER

collaborator

Wesley Research Institute

OTHER

lead

Trans Tasman Radiation Oncology Group

OTHER

NCT00141648 - Chemotherapy and Radiotherapy for Osteolymphoma | Biotech Hunter | Biotech Hunter